Zydus Cadila has received final USFDA approval to market Telmisartan and Hydrochlorothiazide tablets used in the treatment of hypertension.
The company will market the drug in the strengths of 40 mg/12.5 mg, 80 mg/25 mg and will manufacture the drug at its formulations manufacturing facility in Moraiya, Ahmedabad. According to industry estimates, the total sales of Telmisartan and Hydrochlorothiazide tablets is estimated at $66.5 million.
Company Profile : Cadila Healthcare Ltd
Leave a Reply